IProteos, a spin-off from IRB Barcelona labs and co-funded by the researchers Teresa Tarragó and Ernest Giralt, has received the prize Expoquimia R+D+I for a new drug under development for the treatment of schizophrenia.
The digital newspaper Público and other media have echoed a study headed by the Universitat Autònoma de Barcelona (UAB) and involving researchers from the Chemistry and Molecular Pharmacology Programme at IRB Barcelona that offers a promising advance towards a treatment for Parkinson’s disease,.
Nostrum BioDiscovery has come about from the combined efforts of IRB Barcelona and the BSC-CNS—two research centres of excellence in Barcelona—with the participation of the University of Barcelona and ICREA and supported by the Botín Foundation’s technology transfer programme.
The company boasts cutting-edge bioinformatics technologies to speed up the development and lower the cost of designing drugs—which are becoming increasingly more complex and expensive—and to further precision medicine.
Italian COFUND Postdoctoral Fellow Alessandro Ruffoni (Lecco, 1985) joins the abundant group of athlete-scientists at IRB Barcelona. In January, this pharmaceutical chemist from the University of Milan took up his joint research position in Antoni Riera’s Asymmetric Synthesis’ Lab and Xavier Salvatella’s Molecular Biophysics Lab.